O. Borgå

发表

Two-Fold Interindividual Variation in Plasma Protein Binding of Phenytoin in Patients with Epilepsy

G. Alván, F. Sjöqvist, N. Barth, 1976, Clinical pharmacokinetics.

The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats.

O. Borgå, M. Sababi, U. Hultkvist-Bengtsson, 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure

C. Hoppel, O. Borgå, I. Odar‐Cederlöf, 1979, Clinical pharmacology and therapy.

A Study of Organic Acid Transporter‐Mediated Pharmacokinetic Interaction Between NXY‐059 and Cefuroxime

M. Kågedal, O. Borgå, D. Nilsson, 2007, Journal of clinical pharmacology.

Transfer of terbutaline across the human placenta in late pregnancy.

T. Hedner, L. Enk, O. Borgå, 1985, European journal of respiratory diseases. Supplement.

Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations.

J. Seidegård, O. Borgå, G. Randvall, 2009, Die Pharmazie.

Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses

B. Alexanderson, O. Borgå, 1973, European Journal of Clinical Pharmacology.

Effect of NXY-059, a novel neuroprotectant, on the pharmacokinetics of a single dose of digoxin in healthy subjects

M. Kågedal, O. Borgå, D. Nilsson, 2007, Current medical research and opinion.

Micromethod for the determination of diphenylhydantoin in plasma and cerebrospinal fluid--a comparison between a gas chromatographic and a spectrophotometric method.

F. Sjöqvist, L. Lund, A. Berlin, 1972, Scandinavian journal of clinical and laboratory investigation.

Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects.

C. Edenius, O. Borgå, A. Breitholtz-Emanuelsson, 2002, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke

C. Edenius, O. Borgå, T. Odergren, 2002, European Journal of Clinical Pharmacology.

Active Renal Secretion of NXY‐059, a Novel Neuroprotectant, Is Mediated via an Organic Acid Transporter

O. Borgå, D. Nilsson, Yi-fang Cheng, 2007, Journal of clinical pharmacology.

Pharmacokinetics of enprofylline in healthy elderly subjects

E. Lunell, O. Borgå, 2004, European Journal of Clinical Pharmacology.

Enprofylline pharmacokinetics in children with asthma

O. Borgå, C. Hultqvist, 2004, European Journal of Clinical Pharmacology.

Pharmacokinetics of budesonide in children with asthma

S. Pedersen, O. Borgå, G. Steffensen, 2004, European Journal of Clinical Pharmacology.

Lack of relationship between serum free fatty acids and impaired plasma protein binding of diphenylhydantoin in chronic renal failure

O. Borgå, I. Odar-Cederlöf, 2004, European Journal of Clinical Pharmacology.

Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid

O. Borgå, I. Odar‐Cederlöf, I. Odar-Cederlöf, 1976, Clinical pharmacology and therapeutics.

Protein binding of enprofylline

I. Svensson, O. Borgå, K. Tegner, 2004, European Journal of Clinical Pharmacology.

Serum Protein Binding of Nonsteroidal Antiinflammatory Drugs: A Comparative Study

O. Borgå, B. Borgå, 1997, Journal of Pharmacokinetics and Biopharmaceutics.

PLASMA PROTEIN BINDING, PLASMA CONCENTRATIONS, AND EFFECTS OF DIPHENYLHYDANTOIN IN MAN *

A. Rane, F. Sjöqvist, P. K. Lunde, 1971, Annals of the New York Academy of Sciences.

Effect of cephapirin on tubular reabsorption of amino acids, uric acid and beta 2-microglobulin in man.

G. Alván, O. Borgå, R. Eklöf, 1983, British journal of clinical pharmacology.

Sulindac Exploratory modeling and bioequivalence implications

O. Borgå, J. Harter, V. Hale, 1994 .

Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients

H. Bjermo, O. Borgå, N. Heldring, 2019, Advances in Therapy.

Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder.

O. Borgå, L. Thorsson, S. Edsbäcker, 1999, British journal of clinical pharmacology.

Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis.

U. Malmqvist, M. Korsgren, L. Greiff, 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum.

J. Seidegård, O. Borgå, L. Nyberg, 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study

N. Loman, R. Henriksson, H. Bjermo, 2019, Advances in Therapy.

Protein binding of salicylate in uremic and normal plasma

V. Ringberger, O. Borgå, I. Odar‐Cederlöf, 1976, Clinical pharmacology and therapeutics.

Protein binding of diazepam and digitoxin in uremic and normal serum.

I. Sjöholm, A. Kober, O. Borgå, 1979, Biochemical pharmacology.

Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

F. Sjöqvist, O. Borgå, K. Piafsky, 1978, The New England journal of medicine.

Ceftriaxone: renal and biliary excretion and effect on the colon microflora.

B. Angelin, G. Alván, O. Borgå, 1982, The Journal of antimicrobial chemotherapy.

Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats

A. Mukherjee, O. Borgå, R. Stein, 1996, Inflammation Research.

Kinetics of phenytoin in pregnant and non-pregnant rats.

A. Rane, O. Borgå, Marcela Gutová, 2009, Acta pharmacologica et toxicologica.

A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs.

J. Häggström, H. Nyman, O. Borgå, 2013, Veterinary and comparative oncology.

The role of plasma protein binding in the inhibitory effect of nortriptyline on the neuronal uptake of norepinephrine

B. Hamberger, F. Sjöqvist, O. Borgå, 1970, Clinical pharmacology and therapeutics.

Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole

O. Borgå, A. Couturier, T. Odergren, 2003, European Journal of Clinical Pharmacology.

Plasma protein binding of basic drugs

O. Borgå, K. Piafsky, 1977 .

Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate.

O. G. Nilsen, O. Borgå, K. Piafsky, 1977, Clinical pharmacology and therapeutics.

First pass hydroxylation of nortriptyline: Concentrations of parent drug and major metabolites in plasma

G. Alván, O. Borgå, B. Siwers, 1977, European Journal of Clinical Pharmacology.

The availability of orally administered nortriptyline

G. Alván, B. Alexanderson, O. Borgå, 1973, European Journal of Clinical Pharmacology.

Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis

A. Nilsson, O. Borgå, Z. G-Wagner, 1994, Alimentary pharmacology & therapeutics.

Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

C. Bahr, F. Sjöqvist, M. Reidenberg, 1971, The New England journal of medicine.

Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

O. Borgå, K. Piafsky, 1977, Clinical pharmacology and therapeutics.

Plasma protein binding of tricyclic anti-depressants in man.

D. Azarnoff, F. Sjöqvist, O. Borgå, 1969, Biochemical pharmacology.

Renal elimination of cefoxitin and effect of probenecid after single and repeated doses.

L. Kager, O. Borgå, A. Arvidsson, 1981, Journal of Antimicrobial Chemotherapy.

Effects of probenecid on enprofylline kinetics in man

E. Lunell, O. Borgå, R. Larsson, 2004, European Journal of Clinical Pharmacology.

Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS).

F. Sjöqvist, O. Borgå, Å. Hanngren, 1970, Scandinavian journal of respiratory diseases.

Quantitative Determination of Nortriptyline And Desmethylnortriptyline In Human Plasma By Combined Gas Ciiromatography - Mass Spectrometry

O. Borgå, B. Holmstedt, L. Palmér, 1971 .

Drug interaction: decreased serum concentrations of rifampicin when given with P.A.S.

G. Boman, F. Sjöqvist, A. Malmborg, 1971, Lancet.

The pH‐dependent excretion of mono methylated tricyclic antidepressants; In dog and man

C. Thorstrand, F. Sjöqvist, O. Borgå, 1969 .

Age dependence of renal function: clearance of iohexol and p-amino hippurate in healthy males.

P. Nilsson-ehle, B. Ljungberg, O. Borgå, 1989, Scandinavian journal of clinical and laboratory investigation.

Concentration Dependent Plasma Protein Binding of Salicylate in Rheumatoid Patients

G. Alván, O. Borgå, R. Ekstrand, 1979, Clinical pharmacokinetics.

Measurement of diphenylhydantoin in 0.1-ml plasma samples: gas chromatography and radioimmunoassay compared.

F. Sjöqvist, C. Cook, O. Borgå, 1976, Clinical chemistry.

Kinetics of diphenylhydantoin in uraemic patients: Consequences of decreased plasma protein binding

O. Borgå, I. Odar-Cederlöf, 2004, European Journal of Clinical Pharmacology.

Effect of simultaneous treatment with low doses of perphenazine on plasma and urine concentrations of nortriptyline and 10-hydroxynortriptyline

P. Kragh‐Sørensen, F. Sjöqvist, E. Hvidberg, 1977, European Journal of Clinical Pharmacology.

Decreased plasma protein binding of phenytoin in patients on valproic acid.

R. Dahlqvist, A. Rane, F. Sjöqvist, 1979, British journal of clinical pharmacology.

Identification of 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin as a metabolite of 5,5-diphenylhydantoin (phenytoin) in rats and man.

O. Borgå, M. Garle, Marcela Gutová, 1972, Pharmacology.

A study of the mechanism of the antiasthmatic action of inhaled budesonide.

J. Baskerville, N. Lefcoe, J. Toogood, 1990, The Journal of allergy and clinical immunology.

Interindividual differences in plasma protein binding of nortriptyline in man — A twin study

B. Alexanderson, O. Borgå, 1972, European Journal of Clinical Pharmacology.

Enprofylline kinetics in healthy subjects after single doses

E. Lunell, K. Andersson, L. Edholm, 1983, Clinical pharmacology and therapeutics.

Family study of genetic and environmental factors determining the protein binding of propranolol

G. Alván, L. Iselius, K. Bergström, 2004, European Journal of Clinical Pharmacology.

INHIBITOR OF DRUG-PROTEIN BINDING IN 'VACUTAINERS'

O. Borgå, K. Piafsky, 1976, The Lancet.

Plasma disappearance of nortriptyline in a newborn infant following placental transfer from an intoxicated mother: evidence for drug metabolism.

F. Sjöqvist, P. G. Bergfors, O. Borgå, 1972, The Journal of pediatrics.

Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose

E. Lunell, O. Borgå, R. Larsson, 2004, European Journal of Clinical Pharmacology.

Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers.

M. Hedeland, U. Bondesson, O. Borgå, 2006, International journal of clinical pharmacology and therapeutics.

A convenient method for local drug administration at predefined sites in the entire gastrointestinal tract: experiences from 13 phase I studies.

Bertil Abrahamsson, B. Abrahamsson, J. Seidegård, 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Species differences in the plasma protein binding of desipramine

D. Azarnoff, F. Sjöqvist, O. Borgå, 1968, The Journal of pharmacy and pharmacology.

Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole.

J. Seidegård, O. Borgå, L. Nyberg, 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Distribution of Enprofylline and Theophylline Between Plasma and Cerebrospinal Fluid

O. Borgå, B. Weeke, L. Laursen, 1989, Therapeutic drug monitoring.

NXY‐059 Does Not Significantly Interact With Furosemide in Healthy Volunteers

A. Grahnén, O. Borgå, D. Nilsson, 2006, Journal of clinical pharmacology.

Plasma disappearance of transplacentally transferred diphenylhydantoin in the newborn studied by mass fragmentography

F. Sjöqvist, O. Borgå, M. Garle, 1974, Clinical pharmacology and therapeutics.

Kinetics of nortiptyline (NT) in rats in vivo and in the isolated perfused liver: demonstration of a 'first pass disappearance' of NT in the liver.

M. Rowland, E. Fellenius, O. Borgå, 1973, Pharmacology.

Pharmacokinetics and biological effects of nortriptyline in man.

M. Åsberg, L. Bertilsson, B. Hamberger, 2009 .

Renal excretion of cephapirin and cephaloridine: Evidence for saturable tubular reabsorption

O. Borgå, A. Arvidsson, Olof Borgå, 1979, Clinical pharmacology and therapeutics.

Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors.

I. Sjöholm, A. Kober, O. Borgå, 1976, Biochemical pharmacology.

Techniques for plasma protein binding of demethylchlorimipramine

R. Braithwaite, L. Bertilsson, O. Borgå, 1979, Clinical pharmacology and therapeutics.

Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole.

J. Seidegård, O. Borgå, L. Nyberg, 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Studies on the metabolism and pharamcokinetics of nortriptyline and desmethylimipramine in man.

L. Bertilsson, B. Alexanderson, F. Sjöqvist, 1971, Chemico-biological interactions.

Plasma protein binding of propranolol in disease states [proceedings].

F. Sjöqvist, O. Borgå, K. Piafsky, 1977, British journal of clinical pharmacology.